Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus 177Lu-DOTATATE for refractory grade 2–3 meningioma (ELUMEN)
2023-508400-38-00Phase 2Authorised
- Sponsor
- CHRU Nancy
- Start
- Apr 2024
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and lutetium Lu 177 dotatate in meningioma, sponsored by CHRU Nancy. Primary endpoint: PFS-6. Planned start Apr 2024; status: authorised.
02
Drugs
everolimuslutetium Lu 177 dotatate
03
Conditions
meningioma
Beyond the preview
Go deeper on 2023-508400-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508400-38-00.